Your Government Can Stop HIV for $40 a Year. Why Won't It?

Forty dollars. That is what it now costs, per person, per year, to protect someone from HIV with a shot needed only twice a year. Forty dollars is less than many families spend on groceries in a single week in Lusaka, Kampala, or Maputo. For the price of a cheap phone accessory, a mother in Lagos could stop a virus from taking her daughter's future.

For years we were told this was impossible, or at least that it would take a decade. Now a generic version of lenacapavir has cleared the U.S. Food and Drug Administration, and the promise is on the table for 120 low- and middle-income countries. Let us be clear about what this means. The science has already done its job. Two large trials of people at high risk found that lenacapavir nearly eliminated new infections. The question left is no longer whether this works. The question is whether our governments, our health ministries, and our international partners will move with the urgency that a dying generation deserves.

Consider the numbers we already know. Sub-Saharan Africa carries roughly two-thirds of the world's people living with HIV. Globally, around 1.3 million people were newly infected in 2023, and a large share of those infections were on our continent, among young women and adolescent girls in particular. Adolescent girls and young women in parts of southern and eastern Africa face infection rates several times higher than their male peers. They are not infected because they lack knowledge. They are infected because the tools to protect them have been too expensive, too frequent, too hard to access, or simply absent from the clinics where they live.

The daily pill has been the default prevention option, and it works when taken consistently. But consistency is a luxury when you are a teenager with no privacy at home, a market trader who cannot take a pill at the same hour every day, or a woman whose partner controls her choices. A twice-yearly injection removes much of that burden. It does not depend on remembering a bottle. It does not announce your status to your family. It gives people a shield they do not have to fight for daily.

So why did it take so long to reach us? Part of the answer lies in patents, pricing, and licensing negotiations that dragged on while infections continued. Gilead Sciences developed the drug and, after pressure from advocates and public health leaders, agreed to license generic production for lower-income markets. That deal deserves recognition. But licensing alone does not deliver medicine to a clinic in Kisumu or Mzuzu. It requires functioning procurement systems, trained nurses, reliable cold chains (though this injection avoids some of those constraints), national regulators willing to recognize quality approvals, and governments that refuse to let the paperwork become a graveyard. Every delay in that chain is a decision made by someone. Every one of those decisions has a body count, even if it never makes the evening news.

Here is the uncomfortable truth we must say out loud. For decades, the rest of the world has treated African HIV as a charity case rather than a governance failure. Donors have funded programs, then shifted priorities. Foreign aid budgets have swung with political winds in Washington, London, and Brussels. Meanwhile, African governments have too often treated health as a line item to trim when the budget gets tight, while they find money for presidential jets, bloated ministerial fleets, and security contracts that never see daylight. When the West lectures us about democracy and accountability, it should start by asking why life-saving medicines are still stuck in customs, stuck in tender processes, or stuck in the political bargaining that our own leaders choose to tolerate.

Look at what the U.S. government's quality-assurance pathway for HIV drugs has achieved over the years. It was built to ensure that medicines bought for other countries meet safety standards. This generic approval shows that when rules are predictable and institutions are competent, medicine moves. That is a lesson for us. Rules that are transparent and enforced build trust. Rules that are arbitrary and opaque breed corruption and delay.

Africa already has proof that a better path exists. Senegal, once considered a country at serious risk, built a strong, community-centered response and keeps HIV prevalence among the lowest on the continent. Botswana, which faced one of the highest national prevalence rates in the world, turned its epidemic around through sustained treatment rollout and strong state commitment to antiretroviral therapy, backed by a stable, open economy that could finance it. Rwanda's community-based health insurance model shows that pooled, well-managed financing can reach rural households who were once excluded. These are not miracles. They are the product of planning, transparent institutions, and leaders who chose to be measured by results rather than rhetoric.

So what must happen next? First, the African Union and regional economic communities must press national regulators to rely on trusted approvals, such as those from WHO prequalification and stringent regulators, so that generics do not sit in review for years. The African Medicines Agency must be fully operational and adequately funded, not a symbol in a communiqué. Second, finance ministries must put HIV prevention on the core budget, not treat it as a donor-dependent emergency. Third, governments must cut the import duties and tender bottlenecks that make essential medicines more expensive than they should be, and publish procurement timelines so citizens can see where the delay is. Fourth, private pharmacies and community health workers must be licensed and supported to deliver these injections alongside existing services. A free market that rewards competition and quality can drive prices down; a captured market that rewards cronies drives them up.

Now, the call to action. Citizens of Kenya, Nigeria, South Africa, Uganda, Mozambique, Zambia, and every other nation on this continent must ask their leaders one question and refuse to accept a vague answer: when will lenacapavir be in our clinics, at what price, and who is accountable if it is late? Demand the timeline in writing. Demand the regulatory approvals published. Demand that parliamentary health committees summon the officials responsible for procurement. Civil society organizations, faith leaders, youth movements, and journalists must track every stage of rollout and name names when targets slip. Those who are asked to wait must not be the first to pay.

We have spent too long being told that our problems are too complicated to solve. HIV prevention at $40 a year is not complicated. It is a choice. A government that delays it is choosing infections. A ministry that loses it in paperwork is choosing funerals. We have the medicine, the price, and the science. What we need now is a generation of leaders who understand that protecting our people is not charity. It is the first duty of sovereignty.

Based on reporting by ACSS-EMAIL